Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.69 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.69 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.69 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 2/20 | 0.51 |
| ▸ | KRAS | P01116 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | POLG | P54098 | 1/20 | 0.47 |
| ▸ | DTYMK | P23919 | 2/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TYMP | P19971 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948896 | 0.96 | POLB (0.70) | POLBP2RY2P2RY4P2RY6FUT5 | |
| Deoxyguanosine SCHEMBL20445785 | 0.93 | POLB (0.67) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL29365434 | 0.93 | P2RY2 (0.62) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL29702417 | 0.93 | P2RY2 (0.62) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL29371610 | 0.93 | P2RY2 (0.62) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL29424735 | 0.93 | P2RY2 (0.62) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL4078522 | 0.93 | P2RY2 (0.62) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL8613676 | 0.92 | P2RY2 (0.62) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL8614074 | 0.92 | P2RY2 (0.62) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL20710403 | 0.92 | POLB (0.81) | POLBP2RY2P2RY4P2RY6FUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144623-A1 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY | SIRNA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11529428-B2 | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety | BANK OF AMERICA, N.A. | 2022-12-20 | — | — | US | disclosed |
| US-20210008226-A1 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY | BANK OF AMERICA, N.A. | 2021-01-14 | — | — | US | disclosed |
| US-10729787-B2 | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety | SIRNA THERAPEUTICS, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10004814-B2 | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety | SIRNA THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3068407-A1 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY | Sirna Therapeutics, Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160256570-A1 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (siNA) CONJUGATED TO A LIPOPHILIC MOIETY | SIRNA THERAPEUTICS, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2015070158-A1 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY | SIRNA THERAPEUTICS, INC. (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144623-A1 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY | TNNC1, MYOF, MSTN | POLB 649/4885P2RY2 4873/4885P2RY4 4881/4885 |
| US-10729787-B2 | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety | TNNC1, MYOF, MSTN | POLB 649/4885P2RY2 4873/4885P2RY4 4881/4885 |
| US-20210008226-A1 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY | TNNC1, MYOF, MSTN | POLB 649/4885P2RY2 4873/4885P2RY4 4881/4885 |
| US-10004814-B2 | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety | TNNC1, MYOF, MSTN | POLB 649/4885P2RY2 4873/4885P2RY4 4881/4885 |
| US-20160256570-A1 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (siNA) CONJUGATED TO A LIPOPHILIC MOIETY | TNNC1, MYOF, MSTN | POLB 649/4885P2RY2 4873/4885P2RY4 4881/4885 |
| US-11529428-B2 | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety | TNNC1, MYOF, MSTN | POLB 649/4885P2RY2 4873/4885P2RY4 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.